25 May 2018

Statement delivered by Paula Barbosa, IFPMA, Manager, Vaccines Policy

Mr Chairman,

IFPMA and its member companies would like to confirm our continued collaboration in the context of pandemic preparedness and response efforts. Through the PIP Framework, influenza vaccine and antiviral manufacturers have helped the WHO secure 405 million doses of influenza vaccine and 10 million doses of antivirals to be used in the event of an influenza pandemic. IFPMA member companies have also contributed most of the US$142 million voluntary donations collected by March 2018, by the WHO PIP Framework.

In line with the WHO draft thirteenth General Programme of Work, IFPMA particularly welcomes WHO efforts to measure impact and improve partnerships, communications, accountability and financing, to resource the strategic priorities as well as foster cultural changes to ensure a seamless, high-performing WHO.

IFPMA remains committed partners in helping WHO achieve their public health objectives, and in this case, ensuring that the world is better prepared to respond to the next influenza pandemic.

Thank you.

About IFPMA

IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.

To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.

ifpma.org

Media Contact

Elliot Dunster e.dunster@ifpma.org